Dr. Michael Guerrera, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Medical school
- University of Connecticut School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Connecticut School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
VA license 0101273594 · DC license MD31602 -
Pediatrics Physician
VA license 0101273594
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital (212 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 16 payments worth $46,559 in total to this clinician.
| Genzyme Corporation | $31,842 |
|---|---|
| Sanofi US Services Inc. | $14,718 |
| Compensation for services other than consulting (speaking, faculty) | $28,255 |
|---|---|
| Consulting Fee | $14,718 |
| Travel and Lodging | $3,258 |
| Food and Beverage | $329 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Sep 27, 2025 | Consulting Fee | $14,718 |
| Genzyme Corporation Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $9,141 |
| Genzyme Corporation Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) ELOCTATE; ALTUVIIIO · Hematology | $8,726 |
| Genzyme Corporation Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $8,726 |
| Genzyme Corporation Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $1,662 |
| Genzyme Corporation Jun 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Syracuse, NY · in-kind | $1,110 |
| Genzyme Corporation Jun 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Syracuse, NY · in-kind | $967 |
| Genzyme Corporation Oct 8, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Richmond, VA · in-kind | $949 |
| Genzyme Corporation Jun 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Syracuse, NY · in-kind | $215 |
| Genzyme Corporation Jun 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Syracuse, NY | $16.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,738 in research payments for these studies, mostly to the institutions running them.
- A phase 3, prospective, multicenter, uncontrolled, open-label clinical study to determine the efficacy, safety, and tolerability of rvwf with or without advate in the treatment and control of bleeding episodes, the ef…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.